TD Cowen Maintains Buy on Medpace Hldgs, Lowers Price Target to $372
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Charles Rhyee maintains a Buy rating on Medpace Holdings (NASDAQ:MEDP) but lowers the price target from $413 to $372.
October 23, 2024 | 6:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TD Cowen's analyst Charles Rhyee continues to recommend buying Medpace Holdings but has reduced the price target from $413 to $372, indicating a more conservative outlook.
The Buy rating suggests continued confidence in Medpace's potential, but the lowered price target reflects a more cautious stance on its near-term valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100